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Objectives. To determine dose-related clinical and neurohu-
moral effects of angiotensin-converting enzyme (ACE) inhibitors
in patients with chronic heart failure (CHF), we conducted a
double-blind, placebo-controlled, randomized study of three doses
(2.5 mg, 5 mg and 10 mg) of the long-acting ACE inhibitor
imidapril.
Background. The ACE inhibitors have become a cornerstone in
the treatment of CHF, but whether high doses are more effective
than low doses has not been fully elucidated, nor have the
mechanisms involved in such a dose-related effect.
Methods. In a parallel group comparison, the effects of three
doses of imidapril were examined. We studied 244 patients with
mild to moderate CHF (New York Heart Association class II–III:
680%/20%), who were stable on digoxin and diuretics. Patients
were treated for 12 weeks, and the main end points were exercise
capacity and plasma neurohormones.
Results. At baseline, the four treatment groups were well-
matched for demographic variables. Of the 244 patients, 25
dropped out: 3 patients died, and 9 developed progressive CHF
(3/182 patients on imidapril vs. 6/62 patients on placebo, p <
0.05). Exercise time increased 45 s in the 10-mg group (p 5 0.02
vs. placebo), but it did not significantly change in the 5-mg
(116 s), and 2.5-mg (111 s) imidapril group, compared to placebo
(13 s). Physical working capacity also increased in a dose-related
manner. Plasma brain and atrial natriuretic peptide decreased
(p < 0.05 for linear trend), while (nor)epinephrine, aldosterone
and endothelin were not significantly affected. Renin increased in
a dose-related manner, but plasma ACE activity was suppressed
similarly (660%) on all three doses.
Conclusions. Already within 3 months after treatment initia-
tion, high-dose ACE inhibition (with imidapril) is superior to
low-dose. This is reflected by a more pronounced effect on exercise
capacity and some of the neurohormones, but it does not appear
to be related to the extent of suppression of plasma ACE.
(J Am Coll Cardiol 1998;32:1811–8)
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Angiotensin-converting enzyme (ACE) inhibitors have be-
come a cornerstone in the treatment of chronic heart failure
(CHF), as these drugs reduce morbidity and mortality in CHF
(1). In most CHF trials, however, relatively high doses of ACE
inhibitors were used, but in clinical practice much lower doses
are often prescribed (2), and data from a recent large study in
patients with moderate to severe CHF showed that only 25%
of all patients were on full-dose ACE inhibition (3). Still, there
are many theoretical considerations why higher doses might be
more effective (4,5), and it is generally recommended to try to
achieve the target doses of ACE inhibitors (1,6). Assuming
such a dose-dependent effect, it is important, however, to
elucidate which mechanisms are involved. Because the effect of
ACE inhibitors is due to hemodynamic and neurohormonal
factors, such studies should focus on both parameters, but so
far only few data are available on this issue.
Imidapril hydrochloride is a long-acting, orally active,
nonsulphydryl-containing ACE inhibitor that has been used in
hypertension, CHF and after myocardial infarction (7–12).
Imidapril is a pro-drug that is converted by the liver to its active
metabolite imidaprilat. It has a potent hypotensive effect, and
the inhibition of ACE lasts significantly longer in tissue than in
plasma. In hypertensive patients, blood pressure was still
decreased 24 h after imidapril administration in a dose-
dependent manner; plasma ACE was still 60% suppressed at
this time (8). Maximal reduction in blood pressure and plasma
ACE was achieved with 10 mg imidapril once daily (8,9), and
with increasing doses no additional effect was found (8). When
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administered to patients with acute myocardial infarction,
imidapril was found to improve left ventricular ejection frac-
tion and to reduce plasma brain natriuretic peptide (BNP)
levels (11). In patients with CHF (New York Heart Associa-
tion [NYHA] functional class II–III), 2.5 mg and 5 mg
imidapril lowered plasma ACE to a similar extent, whereas the
effect on blood pressure was more pronounced on 5 mg
imidapril (12).
In the present study, we examined the dose-related clinical
and neurohormonal effects of three doses (2.5 mg, 5 mg and
10 mg) of imidapril during 12 weeks of treatment, compared to
placebo in patients with stable mild to moderate CHF, who
were treated with digoxin and diuretics.
Methods
Study design. The study was a double-blind, placebo-
controlled, randomized, parallel group comparison of three
different doses of imidapril once daily. It was carried out in 25
centers in The Netherlands, Germany and Belgium (see Ap-
pendix). The study started with a single-blind, placebo run-in
period of 2 weeks, during which the clinical stability of patients
was confirmed and the bicycle exercise test was repeated. The
second part was a double-blind phase of 12 weeks’ duration,
and patients were randomized to one of the four treatment
arms. During this phase, the imidapril dose was gradually
increased in a double-blind manner during the first 3 weeks: all
patients who were randomized to active treatment (three of
the four groups) received 2.5 mg during the first week. The
dose was then increased to 5 mg in the 5- and 10-mg groups in
the second week, and in the third week it was uptitrated to
10 mg in the 10-mg group only. After randomization, patients
were seen on weeks 1, 2, 3, 8 and 12. The protocol was
conducted in accordance with the revised declaration of Hel-
sinki, and was approved by the Ethics Committee of each
hospital. All patients gave their written informed consent
before entering the study.
Patients. Subjects were eligible if they met the following
criteria: 1) signs and symptoms of mild to moderate CHF
(NYHA class II–III); 2) aged 21 to 75 years (females were
postmenopausal, or taking contraceptive medication); 3) a left
ventricular ejection fraction ,0.45; and 4) a minimal exercise
duration .2 min, and a maximal exercise duration of 12 and
10 min, respectively, for men and women ,46 years, of 10 and
8 min for subjects 46 to 60 years, and 8 and 6 min for subjects
.60 years. A 20% difference in exercise was allowed between
the two baseline tests (the shorter exercise duration serving as
the 100% value), and both tests were limited by dyspnea and/or
fatigue.
Patients were excluded from participation if they had
hemodynamically significant valvular disease, active myocardi-
tis, thyroid disease or hypertrophic cardiomyopathy, a history
of myocardial infarction or open heart surgery ,3 months,
severe hypertension (requiring treatment other than diuretics)
or hypotension (supine systolic blood pressure ,100 mm Hg),
angina pectoris (limiting exercise capacity as well as unstable
complaints), atrial fibrillation (requiring other than digitalis
therapy), supraventricular or ventricular arrhythmias requiring
treatment (antiarrhythmic drugs and pacemakers not allowed),
right-sided CHF, significant electrolyte abnormalities, any
other relevant disease (including anemia) and significant over-
or underweight from normal. Patients with known or suspicion
of bilateral renal artery stenosis, and those with significant
impaired renal function (serum creatinine .1.8 mg/dl or .160
mmol/liter) or renal transplantation were also excluded. Pa-
tients who had a history of substance abuse were also not
included. The following drugs were not allowed: vasodilators
(including calcium channel blockers) except for nitrates,
b-blockers, potassium-retaining diuretics, lithium, allopurinol,
cytostatic or immunosuppressive agents, neuroleptics, imipra-
mine, and nonsteroidal anti-inflammatory drugs except aspirin.
Also, ACE inhibitor therapy was not allowed within 4 weeks
prior to the start of the study (56 weeks prior to randomiza-
tion), and patients with known intolerance were also excluded.
Exercise protocol. During the run-in phase, exercise testing
was performed twice (see above), and it was repeated after 8
and 12 weeks of double-blind treatment. Exercise testing was
performed in the morning between 9 and 10 AM, before intake
of study medication; it was intended that this test was carried
out 24 6 4 h after intake of the previous study medication, and
2 to 4 h after a light breakfast, without coffee or tea. Exercise
testing was carried out in the sitting position, using an electri-
cally braked bicycle ergometer. The protocol started with a
workload of 50 W, and was increased with steps of 10 W; each
step was maintained for 1 min. Heart rate and blood pressure
were measured before and throughout the test, and the
electrocardiogram was monitored continuously.
Exercise tolerance was assessed by determining total exer-
cise time and physical (or pulse) working capacity (PWC)
determined at 110 beats/min during exercise (PWC110). The
PWC allows us to measure submaximal exercise tolerance and
is not dependent on patients’ motivation (13–15). The PWC is
determined by examining the relationship between heart rate
and power output (in watts). By using PWC, one gets infor-
mation on how many watts (W) can be reached at a certain
heart rate. Because of the limited maximal pulse reached by
CHF patients during exercise testing, we (prospectively) chose
110 beats/min, but in healthy subjects higher heart rates are
often used (13). The PWC110 is calculated as follows:
PWC110 5 W1 1 10 3 ~110 2 P1!/~P2 2 P1!
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANP 5 atrial natriuretic peptide
ATLAS 5 Assessment of Treatment of Lisinopril and Survival
BNP 5 brain natriuretic peptide
CHF 5 chronic heart failure
NYHA 5 New York Heart Association
PWC 5 physical (or pulse) working capacity
1812 VAN VELDHUISEN ET AL. JACC Vol. 32, No. 7
HIGH- VS. LOW-DOSE ACE INHIBITION IN HEART FAILURE December 1998:1811–8
in which W1, P1 and P2 are:
● W1 5 highest stage in watts with a pulse ,110 beats/min
● P1 5 pulse at W1, and P2 5 pulse at W2, which is W1 1
10 W.
The PWC110 was only determined in patients with sinus
rhythm, as the chronotropic response to exercise in atrial
fibrillation and CHF is markedly enhanced and difficult to
quantify (16).
Plasma neurohormones. Measurements were determined
in a subset of patients and performed at three core laboratories
(see Appendix). All samples were taken from an indwelling
venous canula, after .30 min of supine rest, and at peak
exercise. Samples were taken at baseline and at the end of the
study. Plasma norepinephrine (normal value in our laboratory:
100 to 500 pg/ml) and epinephrine (normal: 10 to 70 pg/ml)
were determined by high performance liquid chromatography
with electrochemical detection (17). Active plasma renin (nor-
mal: 5 to 50 mU/ml) was determined with immunoradiometric
assay (Nichols Institute, Bad Nauheim, Germany) (18). Plasma
aldosterone (normal: 50 to 250 pg/ml) was determined by
radioimmunoassay (Coat-a-Count, Diagnostic Products, Los
Angeles, California) (19). Plasma endothelin concentrations
(normal: 1 to 5 pg/ml) were measured by using radioimmuno-
assay (Amersham Buchler, Braunschweig, Germany) (20).
Plasma ACE (normal: 18 to 55 U/I) was determined radiomet-
rically by using (phenyl-4-3H)-hippuryl-glycyl-glycine as a sub-
strate (21,22). Plasma atrial natriuretic peptide (ANP; normal:
50 to 110 pg/ml) and BNP (normal: 25 to 55 pg/ml) were
measured (after SepPak extraction) with kits from the Nichols
Institute, Nijmegen, The Netherlands, and Peninsula Labora-
tories, Belmont, California, respectively (23,24).
Statistical analysis. The primary end point of the study
was change in maximal exercise time after 12 weeks. Secondary
end points were changes in submaximal exercise tolerance
using PWC110, CHF symptomatology, progression of CHF and
neurohormones. In addition, various safety parameters were
assessed. It was estimated that 60 patients per group would be
sufficient to detect a true difference between the medication
groups, with a probability of 90% at an a 5 0.05 significance
level (2-sided, normal distribution).
The primary analysis was performed with the intention-to-
treat population, to ensure that all patients were included in
the analysis, and to avoid bias from missing data, as previously
described (19). In short, we used a nonparametric approach in
which all patients who dropped out were assigned lowest rank,
and missing values were substituted by the lowest exercise
results of that particular group (worst-case analysis). In addi-
tion, only patients who completed the protocol were analyzed
(per protocol population).
Distribution of the baseline variables was compared with
analysis of variance (ANOVA) and the t test (for continuous
variables) and chi-square test (for categoric variables). Differ-
ences among groups after randomization were analyzed at
each scheduled follow-up visit by comparing the mean change
from baseline with use of the ANOVA and the t test. Use of
this procedure avoided any bias that would have been caused
by including baseline data from patients who were subse-
quently withdrawn from the study. Values are mean 6SD
unless indicated otherwise. All p values reported are for
two-tailed test, and a two-tailed alpha of ,0.05 was considered
statistically significant.
Results
A total of 244 patients fulfilled the entry criteria and were
included, and the four treatment groups were well-matched at
baseline (Table 1). Most patients were males, the majority had
rather mild disease (NYHA class II), and coronary artery
disease was the most common underlying disorder. Of the 244
patients, 39 patients (16%) had previously used an ACE
inhibitor, and they were normally divided among the four
groups. During the 12-week study period, three patients died
(sudden death n 5 2, myocardial infarction n 5 1, p 5 NS);
another patient survived an episode of ventricular fibrillation
(Table 2). An additional 21 patients dropped out; therefore,
219 patients completed the protocol. Nine of these 21 patients
developed progressive CHF and discontinued the study; this
drop-out was higher among patients taking placebo (n 5 6 of
62, 10%) than imidapril (n 5 3 of 182, 2%, p , 0.05). The
NYHA class was not significantly affected. Four of the 21
patients discontinued the study because of (probably related)
side effects, including one with dry cough, and one with
angioedema. No other significant side effects were reported,
and no significant biochemical or hematological changes were
observed. All patients in the three imidapril groups were
uptitrated to their maximal dose. Imidapril did not significantly
affect heart rate or blood pressure, neither at rest nor during
exercise, and only small changes in blood pressure were
observed (largest change in systolic pressure 26 6 15 mm Hg
on 10 mg imidapril, p 5 NS).
Exercise capacity. After 8 weeks, no significant improve-
ment in exercise time was observed (imidapril 10 mg: 126 s,
P 5 NS). After 12 weeks, exercise time (intention to treat
analysis) (Fig. 1A) increased 45 6 82 s in patients treated with
10 mg imidapril (p 5 0.018 vs. placebo, and p , 0.05 vs. 2.5 mg
imidapril). Changes in exercise duration in the 5- and 2.5-mg
imidapril groups were not significantly different from placebo.
The dose-response relation was significant for linear-trend
(p 5 0.019). Per protocol analysis (n 5 219) showed similar,
nonsignificant trends (10 mg imidapril: 154 6 78 s; p 5 0.06 vs.
placebo).
After 12 weeks, small but statistically significant differences
in PWC110 (Fig. 1B) were observed between groups (p 5 0.005,
and p 5 0.02 for 10 and 5 mg imidapril vs. placebo, respec-
tively), with a significant dose-related effect by linear trend.
With regard to maximal workload, small and nonsignificant
changes were observed (10-mg imidapril group 19 6 13 W,
p , 0.1 vs. placebo and vs. 2.5 mg imidapril).
Plasma neurohormones. These were available in 82 pa-
tients (placebo n 5 19, imidapril 2.5/5/10 mg, n 5 22/17/24,
respectively). This subgroup was not different from the total
study group, and the four groups were also well balanced. At
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baseline, only plasma ANP and BNP were elevated; other
neurohormones were within the normal range (Table 2).
Plasma norepinephrine concentrations at rest were not
affected by imidapril; during exercise they appeared to be
slightly attenuated (p 5 NS) (Fig. 2A). Epinephrine was also
not affected. Plasma renin at rest slightly increased on all three
doses of imidapril (only significant for 10 mg), but during
exercise this increase was more pronounced (p , 0.05 for all
doses) (Fig. 2B). Furthermore, a dose-response relation by
linear trend was observed both at rest (p 5 0.011) and during
exercise (p , 0.001). Plasma aldosterone and plasma endothe-
lin were not affected, neither at rest nor during exercise.
Plasma ACE (Fig. 2C) was suppressed by 660% on all three
doses (all p , 0.001). Plasma ANP at rest was not significantly
affected by imidapril, although a trend was observed: 236
pmol/liter on 10 mg imidapril, p 5 0.1 vs. placebo. During
exercise, all three imidapril doses decreased ANP, which was
dose dependent (p 5 0.02 for linear trend). Plasma BNP
decreased in the 5-mg and 10-mg imidapril group at rest (both
p , 0.05), and in the 10-mg group during exercise (p , 0.05)
(Fig. 2D). This effect was dose dependent, at rest and during
exercise (p , 0.05).
Table 1. Baseline Characteristics of the Four Treatment Groups
Placebo
(n 5 62)
Imidapril 2.5 mg
(n 5 65)
Imidapril 5 mg
(n 5 57)
Imidapril 10 mg
(n 5 60)
Age (yr) 61 6 9 61 6 9 61 6 9 62 6 9
% Male 71% 82% 81% 75%
LV ejection fraction 0.33 6 0.07 0.34 6 0.10 0.33 6 0.08 0.34 6 0.08
Duration of CHF (months) 31 6 40 32 6 40 36 6 40 40 6 47
NYHA class (%) II 76 74 82 77
III 24 26 18 23
Etiology CHF (%)
Ischemic (coronary disease) 69 60 61 62
Idiopathic cardiomyopathy 23 31 28 18
Other 8 9 11 20
Exercise capacity
Time (s) 406 6 128 447 6 140 461 6 141 462 6 127
PWC110 (watts) 57 6 20 59 6 22 59 6 18 63 6 19
Maximal work load (watts) 85 6 21 92 6 24 94 6 23 93 6 22
Blood pressure (mm Hg)
Systolic 138 6 14 139 6 21 134 6 18 135 6 18
Diastolic 84 6 7 83 6 8 81 6 10 82 6 9
Heart rate (beats/min) 78 6 15 75 6 12 80 6 15 75 6 14
Rhythm (%)
Sinus rhythm 97 86 93 87
Atrial fibrillation 3 14 7 13
Biochemistry (serum)
Sodium (mmol/liter) 141 6 3 141 6 3 141 6 3 141 6 3
Potassium (mmol/liter) 4.4 6 0.3 4.3 6 0.4 4.3 6 0.4 4.3 6 0.4
Creatinine (mmol/liter) 99 6 18 106 6 25 98 6 15 106 6 15
Urea (mmol/liter) 6.4 6 1.8 6.8 6 3.0 6.0 6 1.7 6.2 6 1.3
Plasma neurohormones at rest*
Norepinephrine (pg/ml) 338 6 179 300 6 124 329 6 113 353 6 174
Epinephrine (pg/ml) 35 6 15 37 6 17 37 6 20 30 6 20
Renin (mU/ml) 33 6 31 25 6 24 29 6 20 25 6 12
Aldosterone (pg/ml) 104 6 50 98 6 49 75 6 49 104 6 59
Endothelin (pg/ml) 4.3 6 1.8 4.2 6 1.9 4.5 6 1.8 4.5 6 2.2
ACE (U/l) 27 6 9 27 6 7 27 6 6 27 6 7
ANP (pg/ml) 115 6 49 130 6 63 181 6 96 133 6 50
BNP (pg/ml) 74 6 43 71 6 37 83 6 45 79 6 57
Concomitant drugs (number, %)
Digoxin 19 23 26 24
Diuretics 25 34 25 30
Nitrates 25 21 19 20
Antiplatelet agents 34 22 27 26
Anticoagulants 13 22 18 21
CHF 5 chronic heart failure; LV 5 left ventricular; PWC110 5 physical (or pulse) working capacity at heart rate 110
beats/min. *Only available in 82 patients (see text). There were no significant differences between the groups.
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Discussion
Because they reduce morbidity and mortality, ACE inhibi-
tors have become the most important drugs in the treatment of
CHF. Although the large trials were conducted with high doses
of ACE-inhibition, a large number of CHF patients are using
substantially lower doses (1–6). This practice of prescribing
lower doses may be related to several considerations, such as
the belief that low doses are equally effective but less toxic
(4,5). The present study sheds new light on this issue; it shows
that within 3 months after initiating ACE inhibitor treatment,
a higher dose is clinically more effective than a low dose, an
effect that is paralleled by a dose-related effect on plasma
neurohormones.
Potential explanations. Given the dose-related decrease of
both BNP and ANP during imidapril treatment in this study,
unloading of the heart appears to play an important role.
Natriuretic peptides are released in response to an increase in
intracardiac volume or pressure, both in the atria (ANP) and in
the ventricles (BNP) (25). Furthermore, natriuretic peptides
are related to the severity of CHF and prognosis, and a
decrease could thus be interpreted as a favorable response (6).
An important effect of ACE inhibitors in CHF is unloading of
the heart, thereby preventing cardiac dilatation, and improving
diastolic function (26). The latter was also found to correlate
significantly with a reduction in ANP levels, which is therefore
compatible with the observed (dose-related) effect in the
present study.
A second explanation may be the dose-related improve-
ment in PWC110, which indicates that at a heart rate of 110
beats/min, more work is accomplished, or a lower heart rate is
“required.” While both resting and peak exercise heart rates
were not affected by imidapril, submaximal heart rate was
lower. In CHF, cardiac output during exercise depends on
chronotropic mechanisms, and the present findings would
support a dose-dependent effect of imidapril. Furthermore,
while resting heart rate may be similar in CHF patients of
different severity, during the early stages of exercise it in-
creases more in advanced CHF than in mild CHF (27). This
blunted response of heart rate in mild CHF may be explained
by a reduced sympathetic drive during exercise (28), which was
also observed in the present study.
Several other mechanisms may have played a role in the
observed effects of ACE inhibition in the present study.
Chronic heart failure is accompanied by a decreased skeletal
muscle blood flow, which is an important contributing factor
responsible in the exercise intolerance in these patients. The
ACE inhibitors improve skeletal muscle blood flow (29), and
the present findings may also be related to this. Furthermore,
ACE inhibitors inhibit the degradation of bradykinin and
potentiate its actions, which may also explain part of its
beneficial effects, and in animal studies this effect was also
dose-related (30). Although it may be speculated that both
mechanisms might also have been affected in a dose-related
manner by imidapril, they were not investigated in the present
study.
Previous studies. In two earlier studies with quinapril
in patients with mild CHF, a dose-dependent improvement in
exercise time (31) and hemodynamics (22) was observed. In
advanced CHF, high-dose enalapril was superior to low-dose
for symptomatology, but no difference was observed in exercise
capacity and hemodynamics (32). Recently, the NETWORK
was published, in which 1,532 patients with CHF NYHA class
Figure 1. (A) Change after 12 weeks of treatment in exercise duration
(s) in the four groups. *p , 0.05 vs. placebo; #p , 0.05 vs. 2.5-mg
imidapril. A significant dose-response relation was observed by the
linear trend test (p 5 0.019). (B) Change after 12 weeks of treatment
in physical (or pulse) working capacity (PWC) in watts at a heart rate
of 110 beats/min (PWC110). *p , 0.05 vs. placebo. There was also a
significant dose-response effect (p , 0.05).
Table 2. Reasons for Premature Discontinuation During the Study
(n 5 25 of 244 patients)
Placebo
(n 5 62)
Imidapril
2.5 mg
(n 5 65)
Imidapril
5 mg
(n 5 57)
Imidapril
10 mg
(n 5 60)
Death 1 — 2 —
Progressive CHF 6* 2 1 —
Angina pectoris 1 1 — —
Arrhythmias — — 2# —
Side effects — — 2 2
Other/“unrelated” — 2 1 2
TOTAL 8 5 8 4
*p , 0.05 vs. active medication (3 imidapril groups together). #Including 1
patient who was successfully resuscitated for ventricular fibrillation.
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II–IV were randomized to 2.5, 5 or 10 mg enalapril twice daily
(33). After 6 months, no differences were observed with regard
to mortality or hospitalizations for CHF. Even more recently,
results of the Assessment of Treatment with Lisinopril and
Survival (ATLAS) study have also become available (34). In
that study, 3,164 patients with NYHA class II–IV CHF were
randomized to either low-dose (2.5 or 5 mg) or high-dose (32.5
or 35 mg) lisinopril, and they were followed for almost 4 years.
Although results of the ATLAS study have not yet been fully
published, the data show that, compared to low-dose ACE
inhibition, high-dose lisinopril does not cause a statistically
significant reduction in all-cause mortality, but it is associated
with a significant reduction (212%) in the combined end point
of all-cause mortality and hospitalization. A third large-scale
trial of comparable size (ACHIEVE) is currently still under-
way (6).
Regarding the neurohormonal effects, Nussberger et al.
(22) showed a dose-dependent decrease in angiotensin II after
quinapril, while renin increased. A similar effect was also found
after short-term lisinopril treatment in patients with mild CHF
(24), but in severe CHF (32), neurohormones were not af-
fected in a dose-dependent manner by enalapril. In the present
study, only ANP and BNP were increased at baseline, which
supports their value in mild CHF (35), and confirms that these
neurohormones may also be very useful in the assessment of
drug-induced changes in mild CHF (6).
Inhibition of the renin-angiotensin system. Plasma renin
increased during imidapril treatment in a dose-related manner,
but plasma ACE was suppressed to a similar extent, which
suggests that plasma ACE activity poorly reflects the degree to
which the renin-angiotensin system is suppressed. This is
supported by a recent experimental study in which the degree
of plasma ACE inhibition underestimated local angiotensin I
conversion (36). Furthermore, in a clinical study there was no
correlation between the clinical effects and the degree of
plasma ACE inhibition (37). Therefore, plasma renin (partic-
ularly during exercise) may be a better parameter to judge
dose-related suppression of the renin-angiotensin system.
Plasma renin increases in response to ACE-inhibition both at
rest and during exercise; the latter effect is probably due to an
acute release from the juxtaglomerular cells in the kidney,
which is susceptible to sympathetic blockade (38). Thus, the
higher exercise-related increase in renin with higher doses of
imidapril may reflect larger stores of renin in the kidney, which
suggests a more effective decrease of local angiotensin II, and
confirms the importance of tissue inhibition (39).
Study limitations. Given the rather small patient popula-
tion and the short follow-up, the present results are clearly not
definitive, for they do not provide data on mortality and
(long-term) morbidity. However, this study was designed to
examine whether high-dose ACE inhibition would be superior
to low-dose, with regard to exercise capacity and neurohor-
mones, and in this respect the data may be complementary to
larger survival studies such as ATLAS. A study period of 3
months was chosen because it was deemed unethical to refrain
patients from ACE inhibition any longer at that time. Given
this short follow-up, however, it can also not be excluded that
low-dose imidapril might also have been effective during
prolonged treatment, and in more advanced CHF. In addition,
these data obtained with imidapril should not automatically be
extrapolated to other ACE-inhibitors, as these compounds
may differ—for instance, with regard to tissue penetration (40).
Furthermore, the observed superiority of high-dose ACE
inhibition in mild CHF may not be similar in advanced CHF
(32), which might be due to differences in sensitivity to ACE
inhibition.
Figure 2. (A) Change after 12 weeks of
treatment in plasma norepinephrine con-
centrations (in pg/ml), at rest (open bars)
and peak exercise (solid bars). There are
no significant differences. (B) Change af-
ter 12 weeks of treatment in plasma renin
(mU/ml), at rest (open bars) and peak
exercise (solid bars). *p , 0.05 vs. pla-
cebo; **p , 0.001 vs. placebo; #p , 0.05
vs. 2.5-mg imidapril. The dose-response
relation was significant both at rest and
during exercise (p , 0.05 by linear trend).
(C) Change after 12 weeks of treatment in
plasma ACE (in % from baseline), at rest
(open bars) and peak exercise (solid
bars). All differences are highly significant
vs. placebo (p , 0.001) but there is no
dose-response relation. (D) Change after
12 weeks of treatment in plasma BNP
(pg/ml), at rest (open bars) and peak
exercise (solid bars). *p , 0.05 vs. pla-
cebo. The effect on BNP is dose-
dependent, both at rest and during exer-
cise (both p , 0.05).
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Clinical implications. The present study shows that al-
ready within the first 3 months of initiating ACE inhibitor
treatment with imidapril, high-dose treatment is more effective
than low dose treatment, which is reflected by a preservation of
exercise capacity, and a more pronounced decrease in the
atrial peptides (ANP and BNP). Although the present study
provides insight into underlying mechanisms of dose-related
effects, further data from larger survival trials will be needed to
confirm a dose-dependent effect on prognosis.
Appendix
Participating centers and local investigators:
The Netherlands
Maria Ziekenhuis, Tilburg, H.A.M. van Kesteren; St. Jans Gasthuis Weert,
H.J.A.M. Penn; University Hospital Groningen, D.J. van Veldhuisen; St. Elisa-
beth Ziekenhuis, Tilburg, W.H. Pasteuning; Ziekenhuis Hilversum, K.L. Liem;
Refaja Ziekenhuis, Stadskanaal, L.M. van Wijk; Reinier de Graaf Ziekenhuis,
Delft, A.J.A.M. Withagen; St. Gemini Ziekenhuis, Den Helder, J.G.M. Tans;
Twenteborg Ziekenhuis Almelo, J.L. Darmanata; Het Nieuwe Spittaal, Zutphen,
A.C. Tans.
Belgium
Ziekenhuis Genk, W. Van Mieghem.
Germany
Sta¨dtisches Krankenhaus, Bietigheim-Bissingen, D. Hey; Klinikum Su¨dstadt,
Rostock, G. Naumann; Johannes-Gutenberg-Universita¨t Medizinische Klinik,
Mainz, H. Darius; Krankenhaus Pfungstadt, K.H. Baumgartl; Stadtkrankenhaus
Neuwied, W. Mansury; Stadtkrankenhaus Worms, P. Limbourg; Krankenhaus
Rosenheim, R. Rackwitz; Medizinische Akademie, Erfurt, I. Assmann; Kran-
kenhaus Kaarst, D. Maring; Krankenhaus Bellheim, R. Philipp; Krankenhaus
Berlin, R. Bohm; Krankenhaus Darmstadt, D. Gengnagel; Katharinen-
Krankenhaus, Frankfurt/Main, H.J. Gilfrich; Medizinische Universita¨tsklinik,
Tu¨bingen, R. Haasis.
Core Laboratories for Plasma Neurohumoral Determinations
Plasma (nor)epinephrine, renin, aldosterone, and ACE activities were
determined at Bioscientia, Ingelheim/Rhein, Germany (Dr. A. Schmitt). Plasma
endothelin was determined at Merck KGaA Clinical Research, Darmstadt,
Germany (Dr. A. Klieber), and ANP and BNP were determined at the University
Hospital Dijkzigt, Rotterdam, The Netherlands (Dr. F. Boomsma).
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